DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Meridia (Sibutramine Hydrochloride) - Published Studies

 
 



Meridia Related Published Studies

Well-designed clinical trials related to Meridia (Sibutramine)

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele. [2014]

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. [2011.06]

Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. [2011.03]

Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum. [2010.10.27]

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. [2010.09.02]

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. [2010.09]

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. [2010.09]

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine. [2010.06]

Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. [2010.05]

Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans. [2010.02]

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. [2010.01]

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. [2010.01]

Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. [2010]

Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. [2010]

Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans. [2010]

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. [2010]

Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period. [2009.10.08]

Comparative bioavailability of two formulations of sibutramine. [2009.10]

Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. [2009.09.16]

Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. [2009.08]

Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). [2009.03]

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. [2009]

Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. [2008.11]

A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. [2008.10]

Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). [2008.07.29]

Orlistat and sibutramine beyond weight loss. [2008.06]

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. [2008.05.30]

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. [2008.05]

Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. [2008.03]

Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. [2008.01]

The effect of sibutramine intake on resting and exercise physiological responses. [2008]

Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. [2007.11]

Orlistat and sibutramine beyond weight loss. [2007.10.08]

Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.10]

Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. [2007.07]

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. [2007.06.29]

A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. [2007.06]

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. [2007.04.17]

Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.04.10]

The effect of sibutramine on energy expenditure and body composition in obese adolescents. [2007.04]

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. [2007.02]

The effect of sibutramine on energy expenditure and body composition in obese adolescents. [2007.01.30]

Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. [2006.11]

Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study. [2006.11]

Effects of sibutramine treatment in obese adolescents: a randomized trial. [2006.07.18]

Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. [2006.06.01]

Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. [2006.05]

Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. [2006.05]

[Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial] [2005.09]

Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. [2005.08]

Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. [2005.08]

Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. [2005.07]

Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. [2005.07]

Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. [2005.06]

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. [2005.05]

Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. [2005.05]

Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. [2005.03]

Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. [2005.02]

Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. [2005.02]

Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. [2005.01]

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. [2005.01]

Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. [2004.12]

Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. [2004.12]

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. [2004.12]

Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. [2004.10]

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. [2004.09]

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. [2004.08]

Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. [2004.08]

The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. [2004.06]

The efficacy and safety of sibutramine for weight loss: a systematic review. [2004.05.10]

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. [2004.05]

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. [2004.04]

Food intake with an antiobesity drug (sibutramine) versus placebo and rorschach data: a crossover within-subjects study. [2004.04]

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. [2004.04]

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? [2004.03]

Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. [2004.03]

Cost-effectiveness of sibutramine in the treatment of obesity. [2004.01]

Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers. [2003.11]

A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. [2003.11]

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. [2003.11]

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. [2003.09]

Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. [2003.08]

Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). [2003.08]

Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. [2003.06]

Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. [2003.05]

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. [2003.04.09]

Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. [2003.03]

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. [2003.01]

Paradoxical effect of sibutramine on autonomic cardiovascular regulation. [2002.11.05]

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. [2002.09]

Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. [2002.05]

Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. [2002.02]

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. [2002.02]

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. [2002.01]

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. [2002.01]

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. [2002.01]

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. [2001.11]

Long-term weight loss with sibutramine: a randomized controlled trial. [2001.09.19]

[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects] [2001.09]

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. [2001.09]

Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. [2001.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017